非小细胞肺癌脑转移的放疗进展

doi:10.3760/cma.j.cn371439-20220104-00031

摘要/Abstract

摘要：

脑转移是非小细胞肺癌(NSCLC)患者最常见的远处转移之一,且预后差。化疗、手术对其治疗效果有限。放疗作为标准治疗方式,广泛地应用于临床实践中。单纯放疗包括全脑放疗、立体定向放疗以及全脑放疗联合立体定向放疗。随着放疗的不断发展以及基因测序的进步,放疗现已与靶向药物、抗血管生成药物、免疫药物联合应用在NSCLC脑转移的治疗中,可改善NSCLC脑转移患者的生存。

关键词: 癌,非小细胞肺, 脑转移, 放射治疗, 靶向治疗, 抗血管生成治疗

Abstract:

Brain metastases are one of the most common distant metastases in patients with non-small cell lung cancer (NSCLC), and the prognosis will be extremely poor. The effect of chemotherapy and operation is limited. As a standard treatment, radiotherapy is widely used in clinical practice. Radiotherapy alone includes whole brain radiotherapy, stereotactic radiotherapy and whole brain radiotherapy combined with stereotactic radiotherapy. With the continuous development of radiotherapy and the progress of gene sequencing, radiotherapy has been combined with targeted drugs, anti-angiogenic drugs and immunodrugs in the treatment of NSCLC brain metastasis, which can improve the survival of patients with NSCLC brain metastasis.

Key words: Carcinoma,non-small-cell lung, Brain metastasis, Radiotherapy, Molecular targeted therapy, Antiangiogenic therapy

纪环, 周菊英, 马辰莺, 徐晓婷, 秦颂兵. 非小细胞肺癌脑转移的放疗进展[J]. 国际肿瘤学杂志, 2022, 49(3): 181-184.

Ji Huan, Zhou Juying, Ma Chenying, Xu Xiaoting, Qin Songbing. Progression of radiotherapy for brain metastases in non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 181-184.

参考文献 28

[1]	Ulahannan D, Khalifa J, Faivre-Finn C, et al. Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead[J]. Ann Oncol, 2017, 28(12):2923-2931. DOI: 10.1093/annonc/mdx481. doi: 10.1093/annonc/mdx481 pmid: 29045549
[2]	Tsakonas G, De Petris L, Ekman S. Management of brain metastasized non-small cell lung cancer (NSCLC)—from local treatment to new systemic therapies[J]. Cancer Treat Rev, 2017, 54:122-131. DOI: 10.1016/j.ctrv.2017.02.004. doi: S0305-7372(17)30023-3 pmid: 28254730
[3]	Zhuang H, Yuan Z, Wang J, et al. Phase Ⅱ study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma[J]. Drug Des Devel Ther, 2013, 7:1179-1186. DOI: 10.2147/DDDT.S53011. doi: 10.2147/DDDT.S53011
[4]	Loganadane G, Hendriks L, Le Péchoux C, et al. The current role of whole brain radiation therapy in non-small cell lung cancer patients[J]. J Thorac Oncol, 2017, 12(10):1467-1477. DOI: 10.1016/j.jtho.2017.07.006. doi: 10.1016/j.jtho.2017.07.006
[5]	Suh JH, Kotecha R, Chao ST, et al. Current approaches to the management of brain metastases[J]. Nat Rev Clin Oncol, 2020, 17(5):279-299. DOI: 10.1038/s41571-019-0320-3. doi: 10.1038/s41571-019-0320-3
[6]	Brown PD, Ahluwalia MS, Khan OH, et al. Whole-brain radiothe-rapy for brain metastases: evolution or revolution?[J]. J Clin Oncol, 2018, 36(5):483-491. DOI: 10.1200/JCO.2017.75.9589. doi: 10.1200/JCO.2017.75.9589 pmid: 29272161
[7]	Dziggel L, Gebauer N, Bartscht T, et al. Performance status and number of metastatic extra-cerebral sites predict survival after radiotherapy of brain metastases from thyroid cancer[J]. Anticancer Res, 2018, 38(4):2391-2394. DOI: 10.21873/anticanres.12488. doi: 10.21873/anticanres.12488 pmid: 29599366
[8]	Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC3): a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(8):1049-1060. DOI: 10.1016/S1470-2045(17)30441-2. doi: S1470-2045(17)30441-2 pmid: 28687377
[9]	Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05[J]. Int J Radiat Oncol Biol Phys, 2000, 47(2):291-298. DOI: 10.1016/S0360-3016(99)00507-6. doi: 10.1016/S0360-3016(99)00507-6
[10]	Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase Ⅲ results of the RTOG 9508 randomised trial[J]. Lancet, 2004, 363(9422):1665-1672. DOI: 10.1016/S0140-6736(04)16250-8. doi: 10.1016/S0140-6736(04)16250-8 pmid: 15158627
[11]	Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial[J]. JAMA, 2006, 295(21):2483-2491. DOI: 10.1001/jama.295.21.2483. doi: 10.1001/jama.295.21.2483
[12]	Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study[J]. J Clin Oncol, 2011, 29(2):134-141. DOI: 10.1200/JCO.2010.30.1655. doi: 10.1200/JCO.2010.30.1655
[13]	Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial[J]. JAMA, 2016, 316(4):401-409. DOI: 10.1001/jama.2016.9839. doi: 10.1001/jama.2016.9839 pmid: 27458945
[14]	Boire A, Brastianos PK, Garzia L, et al. Brain metastasis[J]. Nat Rev Cancer, 2020, 20(1):4-11. DOI: 10.1038/s41568-019-0220-y. doi: 10.1038/s41568-019-0220-y
[15]	石远凯, 孙燕, 于金明, 等. 中国肺癌脑转移诊治专家共识(2017年版)[J]. 中国肺癌杂志, 2017, 20(1):1-13. DOI: 10.3779/j.issn.1009-3419.2017.01.01. doi: 10.3779/j.issn.1009-3419.2017.01.01
[16]	Chen H, Wu A, Tao H, et al. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective analysis[J]. Medicine (Baltimore), 2018, 97(44):e13014. DOI: 10.1097/MD.0000000000013014. doi: 10.1097/MD.0000000000013014
[17]	Magnuson WJ, Yeung JT, Guillod PD, et al. Impact of deferring radiation therapy in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who develop brain metastases[J]. Int J Radiat Oncol Biol Phys, 2016, 95(2):673-679. DOI: 10.1016/j.ijrobp.2016.01.037. doi: 10.1016/j.ijrobp.2016.01.037
[18]	Yang WC, Xiao F, Shih JY, et al. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery[J]. Radiother Oncol, 2018, 126(2):368-374. DOI: 10.1016/j.radonc.2017.10.010. doi: 10.1016/j.radonc.2017.10.010
[19]	Du XJ, Pan SM, Lai SZ, et al. Upfront cranial radiotherapy vs. EGFR tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer: a meta-analysis of 1465 patients[J]. Front Oncol, 2018, 8:603. DOI: 10.3389/fonc.2018.00603. doi: 10.3389/fonc.2018.00603
[20]	Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunothe-rapy?[J]. Angiogenesis, 2017, 20(2):185-204. DOI: 10.1007/s10456-017-9552-y. doi: 10.1007/s10456-017-9552-y pmid: 28361267
[21]	Kajal K, Panda AK, Bhat J, et al. Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated tumor-angiogenesis[J]. Sci Rep, 2019, 9(1):4073. DOI: 10.1038/s41598-019-40626-2. doi: 10.1038/s41598-019-40626-2
[22]	Guinde J, Carron R, Tomasini P, et al. Bevacizumab plus radiosurgery for nonsquamous non-small cell lung cancer patients with brain metastases: safe combination?[J]. World Neurosurg, 2017, 107: 1047. e1-1047. e4. DOI: 10.1016/j.wneu.2017.07.185. doi: 10.1016/j.wneu.2017.07.185
[23]	Kim MM, Umemura Y, Leung D. Bevacizumab and glioblastoma: past, present, and future directions[J]. Cancer J, 2018, 24(4):180-186. DOI: 10.1097/PPO.0000000000000326. doi: 10.1097/PPO.0000000000000326
[24]	Mackenzie KJ, Carroll P, Martin CA, et al. cGAS surveillance of micronuclei links genome instability to innate immunity[J]. Nature, 2017, 548(7668):461-465. DOI: 10.1038/nature23449. doi: 10.1038/nature23449
[25]	Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial[J]. Lancet Oncol, 2017, 18(7):895-903. DOI: 10.1016/S1470-2045(17)30380-7. doi: S1470-2045(17)30380-7 pmid: 28551359
[26]	Lehrer EJ, McGee HM, Peterson JL, et al. Stereotactic radiosurgery and immune checkpoint inhibitors in the management of brain metastases[J]. Int J Mol Sci, 2018, 19(10):3054. DOI: 10.3390/ijms19103054. doi: 10.3390/ijms19103054
[27]	Martin AM, Cagney DN, Catalano PJ, et al. Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation[J]. JAMA Oncol, 2018, 4(8):1123-1124. DOI: 10.1001/jamaoncol.2017.3993. doi: 10.1001/jamaoncol.2017.3993
[28]	Colaco RJ, Martin P, Kluger HM, et al. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?[J]. J Neurosurg, 2016, 125(1):17-23. DOI: 10.3171/2015.6.JNS142763. doi: 10.3171/2015.6.JNS142763 pmid: 26544782